On the other hand, we find the nucleophosmin 1 (NPM1) mutation, which is present in approximately 40% of AML patients and has traditionally been associated with a favorable prognosis, particularly in the absence of FLT3 mutation [5]. This evidence concerns the gene FLT3 and acute myeloid leukemia.